SOM Biotech
Barcelona
About SOM Biotech
SOM Biotech is a drug innovation company based on a pioneering AI-based drug discovery technology – SOM AI PRO -, that has built a robust pipeline focused mainly on Orphan CNS products with very high unmet need and blockbuster potential. SOM AI PRO has been validated with 2 successful Phase 2 trials (TTR Amyloidosis, Chorea in Huntington disease), and four programs are at the preclinical stage. SOM Biotech applies the proprietary AI-based drug discovery technology for building its pipeline and strategic collaborations with the companies. The AI technology can be applied in any therapeutic area and allows advancing drug candidates into Phase 2a in less than one year (through 505b2 pathway). It also allows improving the effectiveness of drug discovery and drug life cycle management by the identification of novel targets and indications for the molecules.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $10.0M
- Last round: Series Unknown (Jan 2021)
- Website: sombiotech.com
- Phone: 34 93 402 01 50
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/som-biotech-70446 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.